GILD

Gilead Sciences
D

GILD

Arincen87/100B
166.870
USD
-0.73
(-0.44%)
Pre Open·168.040USD+1.170(+0.70%)
Last updated: · Delayed 15 min

Gilead Sciences shares outstanding 1990–2026

Gilead Sciences had 1,240,338,592 shares outstanding on 8 November 2026. Gilead Sciences had 1.25B diluted shares on average over the last twelve months, down 0.5% on the twelve months before. In fiscal year 2025 the average was 1.26B.

Last updated 9 Nov 2026 · Next report 9 Feb 2027

Shares outstanding

Change on the year

Fiscal yearPeriod endingShares outstandingChange on the yearBasic shares
TTM30 Sept 20261.25B-0.52%1.24B
FY202531 Dec 20251.26B0.00%1.24B
FY202431 Dec 20241.26B-0.24%1.25B
FY202331 Dec 20231.26B-0.32%1.25B
FY202231 Dec 20221.26B0.00%1.26B
FY202131 Dec 20211.26B-0.08%1.26B
FY202031 Dec 20201.26B-1.10%1.26B
FY201931 Dec 20191.28B-2.37%1.27B
FY201831 Dec 20181.31B-0.83%1.30B
FY201731 Dec 20171.32B-2.87%1.31B
FY201631 Dec 20161.36B-10.72%1.34B
FY201531 Dec 20151.52B-7.65%1.46B
FY201431 Dec 20141.65B-2.82%1.52B
FY201331 Dec 20131.69B+7.09%1.53B
FY201231 Dec 20121.58B+0.15%1.51B
FY201131 Dec 20111.58B-9.53%1.55B
FY201031 Dec 20101.75B-6.50%1.71B
FY200931 Dec 20091.87B-2.58%1.81B
FY200831 Dec 20081.92B-0.57%1.84B
FY200731 Dec 20071.93B+5.03%1.86B
FY200631 Dec 20061.84B-3.20%1.84B
FY200531 Dec 20051.90B+2.16%1.82B
FY200431 Dec 20041.86B+15.42%1.73B
FY200331 Dec 20031.61B-2.60%1.61B
FY200231 Dec 20021.65B+2.05%1.56B
FY200131 Dec 20011.62B+11.10%1.52B
FY200031 Dec 20001.46B+6.30%1.46B
FY199931 Dec 19991.37B+4.42%1.37B
FY199831 Dec 19981.31B+26.20%1.31B
FY199731 Dec 19971.04B+16.97%1.04B
FY199631 Dec 1996889.15M+30.61%889.15M
FY199531 Dec 1995680.77M+14.23%680.77M
FY199431 Dec 1994595.94M+16.23%595.94M
FY199231 Dec 1992512.73M+42.42%512.73M
FY199131 Dec 1991360.00M+18.12%360.00M
FY199031 Dec 1990304.76M—304.76M

Figures in USD. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

See also:Revenue,Net income,EPS,Operating income,Cash on hand,Total debt,Free cash flow,Stock buybacks,Income statement

Common questions about Gilead Sciences's shares

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.